Core Insights - Guangzhou Baiyunshan Xihe Health Pharmaceutical Co., Ltd. and Guangdong Huixuan Pharmaceutical Co., Ltd. have signed a strategic framework agreement and a substantive cooperation agreement for the joint development of new medical radioactive isotopes [1] Group 1 - The collaboration focuses on the research and preparation of key new medical radioactive isotopes [1]

Core Viewpoint - Baiyunshan Pharmaceutical Group has shown mixed financial performance with slight revenue growth but a decline in net profit, alongside significant trading activity in its stock [2][3]. Financial Performance - For the first half of 2025, Baiyunshan achieved operating revenue of 41.835 billion yuan, representing a year-on-year increase of 1.93% [2]. - The net profit attributable to shareholders was 2.516 billion yuan, reflecting a year-on-year decrease of 1.31% [2]. Stock Trading Activity - On September 5, Baiyunshan's stock price increased by 0.34%, with a trading volume of 237 million yuan [1]. - The financing buy-in amount for Baiyunshan on the same day was 28.51 million yuan, while the financing repayment was 51.72 million yuan, resulting in a net financing outflow of 23.22 million yuan [1]. - As of September 5, the total financing and securities lending balance for Baiyunshan was 974 million yuan, with the financing balance accounting for 2.61% of the circulating market value [1]. Shareholder Information - As of June 30, 2025, Baiyunshan had 85,500 shareholders, a decrease of 8.54% from the previous period [2]. - The top ten circulating shareholders included Hong Kong Central Clearing Limited, which increased its holdings by 9.36 million shares [3].

Core Points - The company announced a cash dividend of 0.40 CNY per share (before tax) for the first half of 2025, totaling approximately 650.32 million CNY based on the total share capital of 1,625,790,949 shares [1][2][3] Dividend Distribution Plan - The dividend distribution plan was approved at the board meeting on August 15, 2025, following the authorization from the annual general meeting held on June 3, 2025 [1][2] - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the record date [1][2] Taxation Details - For individual shareholders and securities investment funds holding unrestricted A-shares, the company will not withhold personal income tax, resulting in a net cash dividend of 0.40 CNY per share [6] - For qualified foreign institutional investors (QFII), a 10% corporate income tax will be withheld, leading to a net cash dividend of 0.36 CNY per share [7] - Hong Kong investors holding A-shares through the Shanghai-Hong Kong Stock Connect will also have a 10% tax withheld, resulting in a net cash dividend of 0.36 CNY per share [8] Shareholder Meeting Information - The second extraordinary general meeting of 2025 is scheduled for September 26, 2025, at the company's headquarters in Guangzhou [12][14] - The meeting will utilize both on-site and online voting methods, with the online voting system available from 9:15 AM to 3:00 PM on the day of the meeting [14][15] - Shareholders must register by September 25, 2025, to attend the meeting [25]

Core Points - The company announced a cash dividend of RMB 0.40 per share (before tax) for A shares [1][4] - The total cash dividend distribution amounts to RMB 650,316,379.60, based on a total share capital of 1,625,790,949 shares [2][4] - The record date for A shares is September 11, 2025, with the ex-dividend date also on September 12, 2025 [1][3] Dividend Distribution Plan - The cash dividend will be distributed to all shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the record date [2][3] - The company will not withhold individual income tax for personal shareholders holding shares for more than one year, while different tax rates apply for varying holding periods [4][6] - For qualified foreign institutional investors (QFII), a 10% withholding tax will be applied, resulting in a net cash dividend of RMB 0.36 per share [5][6] Implementation Details - The cash dividends for shareholders with designated trading will be distributed through the clearing system of China Securities Depository and Clearing Corporation Limited [3][4] - Shareholders who have not completed designated trading will have their dividends held by the clearing company until the trading is completed [3][4] - The company provides contact information for inquiries regarding the dividend distribution [7]

Group 1 - The company Baiyunshan announced a profit distribution plan for the first half of 2025, proposing a cash dividend of 0.40 yuan per share (tax included) [1] - The record date for the dividend is set for September 11, 2025, with the ex-dividend date and payment date both on September 12, 2025 [1]

此乃要件 請即處理 如 閣下對本通函的任何地方或應採取的行動有任何疑問，應諮詢 閣下的持牌證券 交易商或註冊證券機構、銀行經理、律師、專業會計師或其他專業顧問。 如 閣下已售出或轉讓名下全部本公司的股份，應立即將本通函連同授權委託書送交 買主或承讓人或經手買賣或轉讓之銀行、持牌證券交易商、註冊證券機構或其他代理 商，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部份 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 (1)建議修訂公司章程及取消監事會； (2)建議修訂股東大會議事規則及董事會議事規則； (3)建議補選董事； 及 (4)臨時股東大會通告 本封面頁所用詞彙與本通函內所界定者具有相同涵義。 董事會函件載於本通函第3頁至第7頁。本公司謹定於2025年9月26日（星期五）上午10時 正假座中國廣東省廣州市荔灣區沙面北街45號本公司會議室舉行臨時股東大會。臨時 股東大會之通告載於本通函的第183頁至第185頁。 無論 閣下是否打算出席臨時股東大會， 閣下均須盡快根據隨上述通告 ...

Core Viewpoint - The traditional Chinese medicine (TCM) industry is experiencing structural opportunities driven by policy support, price adjustments, technological innovations, and differentiated demand in the first half of 2025, with notable performance disparities among leading companies [1][3]. Group 1: Company Performance - Yunnan Baiyao achieved revenue of 212.57 billion yuan, a year-on-year increase of 3.92%, and a net profit of 36.33 billion yuan, up 13.93%, marking a historical high for the period [2][4]. - Baiyun Mountain reported revenue growth of 1.93% to 418.35 billion yuan, but net profit fell by 1.31% to 25.16 billion yuan [5][6]. - Huaren Sanjiu's revenue increased by 4.99% to 148.10 billion yuan, while net profit dropped significantly by 24.31% to 18.15 billion yuan [6][10]. - Tongrentang's revenue was 97.69 billion yuan, a slight increase of 0.06%, but net profit decreased by 7.39% to 9.45 billion yuan [5][6]. - Pianzaihuang experienced a revenue decline of 4.81% to 53.79 billion yuan and a net profit drop of 16.22% to 14.42 billion yuan, marking its first revenue decline since its listing in 2003 [4][5]. Group 2: Industry Trends - The TCM industry is transitioning from resource dependence to quality orientation, with enhanced quality control of medicinal materials [3][4]. - The industry is undergoing deep price adjustments, with supply chain pressures and restructuring, leading to a differentiated pricing landscape [3][4]. - The normalization of centralized procurement is accelerating market differentiation within the industry [3]. Group 3: Research and Innovation - Companies are emphasizing innovation as a core driver for growth, with Baiyun Mountain focusing on innovative drugs, generic drug consistency evaluation, and product redevelopment [7][10]. - Pianzaihuang is advancing multiple new drug projects, including 18 research projects and several clinical studies [8]. - Huaren Sanjiu has increased its R&D investment by 68.99% to 6.62 billion yuan, with 205 projects in progress following its acquisition of a 28% stake in Tian Shili [10][11]. - Yunnan Baiyao is integrating AI technologies across its operations, aiming for a digital transformation that enhances efficiency [9].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司2025年半年度權益分派實施公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年9月5日 於本公告日，本公司董事會成員包括執行董事李小軍先生、程寧女士、程洪進先生、唐和平先生與 黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 证券代码：600332 证券简称：白云山 公告编号：2025-068 广州白云山医药集团股份有限公司 2025 年半年度权益分派实施公告 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ⚫ 每股分配比例 A 股每股现金红利 ...

证券代码：600332 证券简称：白云山 公告编号：2025-069 广州白云山医药集团股份有限公司 关于召开2025年第二次临时股东大会的通知 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2025年第二次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 股东大会召开日期：2025年9月26日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 股东大会股权登记日: 2025年9月22日 股东大会召开地点:中国广东省广州市荔湾区沙面北街45号广州白云山 医药集团股份有限公司（"本公司"或"公司"）会议室 本公告仅适用于A股股东,H股股东登记及出席须知请参阅本公司于2025 年9月5日在香港联合交易所有限公司网站（https://www.hkexnews.hk /index_c.htm）刊发的"关于召开2025年第二次临时股东大会的通告"。 方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 月 26 日 10 点 00 分 召开地点：中国广东省广州市荔湾区沙面北街 45 号本 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.40元（含税） 证券代码：600332 证券简称：白云山 公告编号：2025-068 广州白云山医药集团股份有限公司 2025年半年度权益分派实施公告 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/9/11 | － | 2025/9/12 | 2025/9/12 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 公司于 2025 年 6 月 3 日召开的 2024 年年度股东大会授权董事会在满足现金分红条件且 不影响公司正常经营和持续发展的情况下，制定并实施 2025 年中期利润分配方案。本次利润 分配方案经公司于 2025 年 8 月 15 日召开的第九届董事会第二十八次会议审议通过。 二、 分配方案 1. 发放年度：2025年半年度 2. 分派对象： | 股份类别 | 股 ...